PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Schuster, F.R.* ; Stanglmaier, M.* ; Woessmann, W.* ; Winkler, B.* ; Siepermann, M.* ; Meisel, R.* ; Schlegel, P.G.* ; Hess J.* ; Lindhofer, H.G.* ; Borkhardt, A.* ; Buhmann, R.

Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies.

Br. J. Haematol. 169, 90-102 (2015)
DOI
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Summary: Children with B cell malignancies refractory to standard therapy are known to have a poor prognosis and very limited treatment options. Here, we report on the treatment and follow-up of ten patients diagnosed with relapsed or refractory mature B-cell Non Hodgkin Lymphoma (B-NHL), Burkitt leukaemia (B-AL) or pre B-acute lymphoblastic leukaemia (pre B-ALL). All children were treated with FBTA05 (now designated Lymphomun), an anti-CD3 x anti-CD20 trifunctional bispecific antibody (trAb) in compassionate use. Within individual treatment schedules, Lymphomun was applied (a) after allogeneic stem cell transplantation (allo-SCT, n = 6) to induce sustained long-term remission, or (b) stand alone prior to subsequent chemotherapy to eradicate residual disease before allo-SCT (n = 4). Nine of ten children displayed a clinical response: three stable diseases (SD), one partial remission (PR) and five induced or sustained complete remissions (CR). Five of these nine responders died during follow-up. The other patients still maintain CR with a current overall survival of 874-1424 days (median: 1150 days). In conclusion, despite the dismal clinical prognosis of children refractory to standard therapy, immunotherapy with Lymphomun resulted in a favourable clinical outcome in this cohort of refractory paediatric patients.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
4.711
1.602
26
27
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Anti-cd20 X Anti-cd3 ; B-cell Malignancies ; Bispecific Antibody ; Children ; Immunotherapy; Non-hodgkin-lymphoma; Acute-lymphoblastic-leukemia; Lasting Antitumor Immunity; Central-nervous-system; Bispecific Antibody; Allogeneic Lymphocytes; Accessory Cells; Cancer-therapy; Phase Ii/iii; T-cells
Sprache englisch
Veröffentlichungsjahr 2015
HGF-Berichtsjahr 2015
ISSN (print) / ISBN 0007-1048
e-ISSN 1365-2141
Zeitschrift British Journal of Haematology
Quellenangaben Band: 169, Heft: 1, Seiten: 90-102 Artikelnummer: , Supplement: ,
Verlag Wiley
Verlagsort Hoboken
Begutachtungsstatus Peer reviewed
Institut(e) CCG Hematopoetic Cell Transplants (IMI-KHZ)
POF Topic(s) 30504 - Mechanisms of Genetic and Environmental Influences on Health and Disease
Forschungsfeld(er) Immune Response and Infection
PSP-Element(e) G-520300-001
DOI 10.1111/bjh.13242
WOS ID WOS:000351446400012
Scopus ID 84925114367
Scopus ID 84919665118
Erfassungsdatum 2015-01-01
[➜Korrektur melden]